Gloria David, Ph.D., M.H.Sc

Principal Research Scientist

Gloria David

Gloria David, Ph.D., M.H.Sc

Principal Research Scientist

Dr. David serves as Rho PI for the Medical Countermeasures Clinical Studies Network (MCM-CSN) contract funded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA). Under this contract, Rho provides clinical services to facilitate medical countermeasure product development toward licensure. Trials evaluate chemical, biological, radiological, nuclear, pandemic influenza, and emerging infectious diseases countermeasures. Dr. David has served as PI for 2 vaccine studies funded by BARDA: a Phase 2 study to investigate the efficacy of H7 influenza vaccine with adjuvants as a safeguard to the public against pandemic influenza and a Phase 2 study to investigate the safety and immunogenicity of anthrax vaccines in individuals over 65.

Dr. David also currently serves as a Lead Scientist for the Asthma and Allergic Diseases Group for the NIAID Division of Allergy, Immunology, and Transplantation: Statistical and Clinical Coordinating Center (2015-2022). Dr. David has provided scientific and technical leadership for 6 vaccine studies funded by the NIAID. She served as PI on 2 studies in patients with atopic dermatitis examining the safety and immunogenicity of an intradermal influenza vaccine. She also served as co-PI on a study assessing the safety and immunogenicity of the 2009 H1N1 vaccine in adults and children with severe asthma. She has provided leadership for a yellow fever vaccine study and a varicella vaccine study in patients with atopic dermatitis and for a keyhole limpet hemocyanin adjuvant study.

Why infectious disease and vaccines?

“With increasing population density, global travel, and ecological change, emerging infectious diseases (EIDs) pose a growing threat to global health security.   From the beginning of the 21st century to the present, the world has experienced several outbreaks of EIDs, including severe acute respiratory syndrome-related coronavirus (SARS-CoV), H1N1 influenza, Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus, Zika virus, and most recently  SARS-CoV-2.  Vaccines are a critical tool with substantial potential to prevent and reduce the impact of EID outbreaks.  I am passionate about my role in conducting clinical research to support the development of vaccines that may one day save the lives of millions of people throughout the world.”

This is what drives Gloria…

“I have been fortunate enough to have been a part of several clinical trials for the development of vaccines for the treatment of pandemic influenza, including H7N9 and H1N1.  It is very rewarding to me to know that I contributed, in some way, to bringing a safe and effective vaccine for the next potential pandemic to patients.  The ongoing COVID-19 pandemic has highlighted the importance of vaccine research and is a daily reminder that what we do really matters.”